http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 728 reviews. 728 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Stomorgyl

Search a suitable generic or branded drugs, if you could not find the prescribed medicine. This site does not supply any medicines. It contains prices for information purposes only. You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Stomorgyl uses and description

Sort by popularity
Stomorgyl - Pharmacology: Enters bacterial or protozoal cell and impairs synthesis of DNA, resulting in cell death.

Indication: Treatment of serious infections caused by susceptible anaerobic bacteria; prophylaxis of postoperative infection in patients undergoing colorectal surgery; treatment of amebiasis; treatment of trichomoniasis and asymptomatic partners of infected patients; bacterial vaginosis ( Flagyl ER only).

Topical

Treatment of inflammatory papules, pustules, and erythema of acne rosacea.

Vaginal

Treatment of bacterial vaginosis.

Unlabeled Uses

Treatment of hepatic encephalopathy, Crohn disease, antibiotic-associated pseudomembranous colitis, Helicobacter pylori infections.

Used for: Treating infections caused by certain bacteria and preventing infection before, during, and after certain surgeries. It may also be used for other conditions as determined by your doctor.

Stomorgyl is an antibacterial agent. It is thought to work by entering the bacterial cell, acting on some components of the cell, and destroying the bacteria.

Stomorgyl is an anti protozoal agent. It is believed that the mechanism of action is associated with DNA damage-sensitive microorganisms. Active against Trichomonas vaginalis, Gardnerella vaginalis, Giardia lamblia, Entamoeba histolytica, and obligate anaerobic bacteria (including Bacteroides spp., Fusobacterium spp.).

Aerobic bacteria are resistant to metronidazole.

In combination with amoxicillin Stomorgyl is active against Helicobacter pylori. It is believed that amoxicillin inhibits the development of resistance of Helicobacter pylori to metronidazole.

Stomorgyl, a synthetic antibacterial and antiprotozoal agent of the nitroimidazole class, is used against protozoa such as Trichomonas vaginalis, amebiasis, and giardiasis. Stomorgyl is extremely effective against anaerobic bacterial infections and is also used to treat Crohn\'s disease, antibiotic-associated diarrhea, and rosacea.

Indications:

Adult: PO Amoebiasis ; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days. Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections ; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible. Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. IV Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. Rectal Anaerobic infections As supp: 1 g 8 hrly for 3 days, then 12 hrly. Prevention of post-op anaerobic bacterial infections 1 g 8 hrly starting 2 hr pre-op. Topical Bacterial vaginosis As 0.75% gel: Apply 5 g 1-2 times/day for 5 days. Fungating tumours As 0.75 or 0.8% gel: Apply as directed. Rosacea As 0.75% preparation: Apply twice daily. As 1% formulation: Apply once daily.

Oral Amoebiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Balantidiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Blastocystis hominis infection

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Trichomoniasis

Adult: 2 g as a single dose, or 800 mg in the morning and 1.2 g in the evening for 2 days, or 0.6-1 g daily in 2-3 divided doses for 7 days. There should be an interval of 4-6 wk if treatment needs to be repeated.

Child: 1-3 yr: 50 mg tid; 3-7 yr: 100 mg bid; 7-10 yr: 100 mg tid. All doses to be taken for 7 days. Alternatively, 15 mg/kg daily in divided doses for 7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Giardiasis

Adult: 2 g once daily for 3 consecutive days, or 400 mg tid for 5 days, or 500 mg bid for 7-10 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 15 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Bacterial vaginosis

Adult: 2 g as a single dose, or 400-500 mg bid for 5-7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute necrotising ulcerative gingivitis

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute dental infections

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Anaerobic bacterial infections

Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr).

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Prophylaxis of postoperative anaerobic bacterial infections

Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Eradication of H. pylori associated with peptic ulcer disease

Adult: In combination with another antibacterial (e.g. clarithromycin) plus either a proton pump inhibitor (e.g. lansoprazole) or ranitidine bismuth citrate: 400 mg bid. In combination with omeprazole and amoxicillin: 400 mg tid. Continue treatment for 1 wk.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Leg ulcers and pressure sores

Adult: 400 mg tid for 7 days.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Antibiotic-associated colitis

Adult: 250-500 mg bid-tid for 10-14 days. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Child: 20 mg/kg/day 6 hrly. Max dose: 2 g/day. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Anaerobic bacterial infections

Adult: 500 mg infused as 100 ml of a 5 mg/ml solution at 5 ml/min 8 hrly. Alternatively, 15 mg/kg infusion followed by 7.5 mg/kg 6 hrly; infuse over 1 hr (max: 4 g in 24 hr). Substitute oral therapy as soon as possible.

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Prophylaxis of postoperative anaerobic bacterial infections

Adult: 500 mg by IV infusion shortly before operation and repeated 8 hrly; oral doses of 200 or 400 mg 8 hrly being substituted as soon as possible. Patient undergoing colorectal surgery: 15 mg/kg infused over 30-60 min, completed about 1 hr prior to surgery, followed by 2 further IV doses of 7.5 mg/kg infused at 6 and 12 hr after the initial dose.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Topical/Cutaneous Bacterial vaginosis

Adult: Apply 5 g of a 0.75% gel once or bid for 5 days. Rectal Anaerobic infections

Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections.

Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Rectal Prophylaxis of postoperative anaerobic bacterial infections

Adult: 1 g 8 hrly starting 2 hr before surgery.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Topical/Cutaneous Fungating tumours

Adult: Apply as a 0.75 or 0.8% gel to the affected area. Topical/Cutaneous Rosacea

Adult: Apply and rub a thin film once daily (1% formulation) or bid (0.75% formulation) to entire affected areas after washing. Significant response should be noticed within 3 wk. Clinical studies have demonstrated continuing improvement through 9 wk of therapy. Reconstitution: Reconstitute powder for inj by adding 4.4 ml of sterile or bacteriostatic water for inj, 0.9% sodium chloride inj or bacteriostatic sodium chloride inj to a vial labeled as containing 500 mg metronidazole. Reconstituted solution contains approx 100 mg/ml Stomorgyl and must be further diluted with 0.9% sodium chloride inj, 5% dextrose inj or lactated Ringer\'s inj to a concentration of ≤8 mg/ml metronidazole. Neutralise reconstituted and diluted Stomorgyl hydrochloride solution by adding approx 5 mEq of sodium bicarbonate inj for each 500 mg metronidazole. Incompatibility: Incompatible with aztreonam, dopamine, meropenem.

Stomorgyl is an antibiotic. It is used to treat bacterial infection of the vagina, commonly known as bacterial vaginosis or vaginitis.

Stomorgyl is an antibiotic. It is used to treat certain skin infections or skin inflammation. Stomorgyl gel or cream is used to treat acne rosacea (commonly known as "adult acne"), in which inflammation of the facial skin causes a red, patchy colouration of the face and the appearance of acne-like pimples. Stomorgyl helps to reduce the redness and the number of pimples. Stomorgyl is also used to treat infection of decubitus ulcers (commonly known as "bed sores" or "pressure sores"). It can also be used to treat other types of skin and soft tissue ulcers, such as diabetic foot ulcers, varicose vein ulcers, ulcers in breast cancer and ulcers that are caused by radiotherapy. Stomorgyl is also used to treat a serious gum disease called periodontitis and other dental problems such as alveolar osteitis (commonly known as "dry socket", which can occur after certain types of tooth extractions such as a wisdom tooth extraction). Stomorgyl is also used to treat perioral dermatitis, a facial rash that occurs around the mouth.

Stomorgyl is an antibiotic. It is used to treat dental, brain, lung, skin, vagina, bone, joint, digestive tract and blood infections. Stomorgyl is also used to treat and prevent infections after an operation. It may also be used to treat certain sexually-transmitted diseases (STD). Stomorgyl suppositories are usually given when you are not able to swallow oral medication. Once you are well enough to take your medicines by mouth, your doctor will usually change to the pill or syrup form of Metronidazole.

Stomorgyl is an antibiotic. It is used to treat dental, lung, skin, vagina, bone and joint infections, infection of the digestive tract and certain sexually transmitted diseases (STD). It is also used together with other medicines for gastric ulcers caused by a type of bacteria known as Helicobacter pylori.

Oral Amoebiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Balantidiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Blastocystis hominis infection

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Trichomoniasis

Adult: 2 g as a single dose, or 800 mg in the morning and 1.2 g in the evening for 2 days, or 0.6-1 g daily in 2-3 divided doses for 7 days. There should be an interval of 4-6 wk if treatment needs to be repeated.

Child: 1-3 yr: 50 mg tid; 3-7 yr: 100 mg bid; 7-10 yr: 100 mg tid. All doses to be taken for 7 days. Alternatively, 15 mg/kg daily in divided doses for 7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Giardiasis

Adult: 2 g once daily for 3 consecutive days, or 400 mg tid for 5 days, or 500 mg bid for 7-10 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 15 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Bacterial vaginosis

Adult: 2 g as a single dose, or 400-500 mg bid for 5-7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute necrotising ulcerative gingivitis

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute dental infections

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Anaerobic infections

Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr).

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Prevention of postoperative anaerobic bacterial infections

Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Eradication of H. pylori associated with peptic ulcer disease

Adult: In combination with another antibacterial (e.g. clarithromycin) plus either a proton pump inhibitor (e.g. lansoprazole) or ranitidine bismuth citrate: 400 mg bid. In combination with omeprazole and amoxicillin: 400 mg tid. Continue treatment for 1 wk.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Leg ulcers and pressure sores infected with anaerobic bacteria

Adult: 400 mg tid for 7 days.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Antibiotic-associated colitis

Adult: 250-500 mg bid-tid for 10-14 days. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Child: 20 mg/kg/day 6 hrly. Max dose: 2 g/day. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Anaerobic infections

Adult: 500 mg infused as 100 ml of a 5 mg/ml solution at 5 ml/min 8 hrly. Alternatively, 15 mg/kg infusion followed by 7.5 mg/kg 6 hrly; infuse over 1 hr (max: 4 g in 24 hr). Substitute oral therapy as soon as possible.

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Prevention of postoperative anaerobic bacterial infections

Adult: 500 mg by IV infusion shortly before operation and repeated 8 hrly; oral doses of 200 or 400 mg 8 hrly being substituted as soon as possible. Patient undergoing colorectal surgery: 15 mg/kg infused over 30-60 min, completed about 1 hr prior to surgery, followed by 2 further IV doses of 7.5 mg/kg infused at 6 and 12 hr after the initial dose.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Rectal Anaerobic infections

Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections.

Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Rectal Prevention of postoperative anaerobic bacterial infections

Adult: 1 g 8 hrly starting 2 hr before surgery.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Topical/Cutaneous Bacterial vaginosis

Adult: Apply 5 g of a 0.75% gel once or bid for 5 days. Topical/Cutaneous Adjunct to treatment of chronic periodontal infections

Adult: Apply 25% dental gel to affected area. Topical/Cutaneous Reduction of odour associated with anaerobic infection in fungating tumours

Adult: Apply as a 0.75 or 0.8% gel to the affected area. Topical/Cutaneous Rosacea

Adult: Apply and rub a thin film once daily (1% formulation) or bid (0.75% formulation) to entire affected areas after washing. Significant response should be noticed within 3 wk. Clinical studies have demonstrated continuing improvement through 9 wk of therapy. Reconstitution: Reconstitute powder for inj by adding 4.4 ml of sterile or bacteriostatic water for inj, 0.9% sodium chloride inj or bacteriostatic sodium chloride inj to a vial labeled as containing 500 mg metronidazole. Reconstituted solution contains approx 100 mg/ml Stomorgyl and must be further diluted with 0.9% sodium chloride inj, 5% dextrose inj or lactated Ringer\'s inj to a concentration of ≤8 mg/ml metronidazole. Neutralise reconstituted and diluted Stomorgyl hydrochloride solution by adding approx 5 mEq of sodium bicarbonate inj for each 500 mg metronidazole. Incompatibility: Incompatible with aztreonam, dopamine, meropenem.

Oral Amoebiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Balantidiasis

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Blastocystis hominis infection

Adult: 400-800 mg tid for 5-10 days or 1.5-2.5 g as a single daily dose for 2-3 days. Alternatively, 1.5-2.5 g as a single dose for 2-3 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 35-50 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Trichomoniasis

Adult: 2 g as a single dose, or 800 mg in the morning and 1.2 g in the evening for 2 days, or 0.6-1 g daily in 2-3 divided doses for 7 days. There should be an interval of 4-6 wk if treatment needs to be repeated.

Child: 1-3 yr: 50 mg tid; 3-7 yr: 100 mg bid; 7-10 yr: 100 mg tid. All doses to be taken for 7 days. Alternatively, 15 mg/kg daily in divided doses for 7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Giardiasis

Adult: 2 g once daily for 3 consecutive days, or 400 mg tid for 5 days, or 500 mg bid for 7-10 days.

Child: 1-3 yr: ¼ adult dose; 3-7 yr: 1 / 3 adult dose; 7-10 yr: ½ adult dose. Alternatively, 15 mg/kg daily in divided doses.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Bacterial vaginosis

Adult: 2 g as a single dose, or 400-500 mg bid for 5-7 days.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute necrotising ulcerative gingivitis

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Acute dental infections

Adult: 200 mg tid for 3 days.

Elderly: Dose reductions may be required. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Anaerobic bacterial infections

Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr).

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Prophylaxis of postoperative anaerobic bacterial infections

Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Eradication of H. pylori associated with peptic ulcer disease

Adult: In combination with another antibacterial (e.g. clarithromycin) plus either a proton pump inhibitor (e.g. lansoprazole) or ranitidine bismuth citrate: 400 mg bid. In combination with omeprazole and amoxicillin: 400 mg tid. Continue treatment for 1 wk.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Leg ulcers and pressure sores

Adult: 400 mg tid for 7 days.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Oral Antibiotic-associated colitis

Adult: 250-500 mg bid-tid for 10-14 days. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Child: 20 mg/kg/day 6 hrly. Max dose: 2 g/day. Transfer to oral vancomycin is recommended if there is no clear clinical response after 2 days of treatment.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Anaerobic bacterial infections

Adult: 500 mg infused as 100 ml of a 5 mg/ml solution at 5 ml/min 8 hrly. Alternatively, 15 mg/kg infusion followed by 7.5 mg/kg 6 hrly; infuse over 1 hr (max: 4 g in 24 hr). Substitute oral therapy as soon as possible.

Child: 7.5 mg/kg 8 hrly.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Intravenous Prophylaxis of postoperative anaerobic bacterial infections

Adult: 500 mg by IV infusion shortly before operation and repeated 8 hrly; oral doses of 200 or 400 mg 8 hrly being substituted as soon as possible. Patient undergoing colorectal surgery: 15 mg/kg infused over 30-60 min, completed about 1 hr prior to surgery, followed by 2 further IV doses of 7.5 mg/kg infused at 6 and 12 hr after the initial dose.

Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Topical/Cutaneous Bacterial vaginosis

Adult: Apply 5 g of a 0.75% gel once or bid for 5 days. Rectal Anaerobic infections

Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections.

Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Hepatic impairment: Severe: 1 / 3 of usual dose given once daily. Rectal Prophylaxis of postoperative anaerobic bacterial infections

Adult: 1 g 8 hrly starting 2 hr before surgery.

Elderly: Dose reduction may be necessary. CrCl (ml/min) Dosage Recommendation <10 Consider reducing dose during long-term therapy. Topical/Cutaneous Fungating tumours

Adult: Apply as a 0.75 or 0.8% gel to the affected area. Topical/Cutaneous Rosacea

Adult: Apply and rub a thin film once daily (1% formulation) or bid (0.75% formulation) to entire affected areas after washing. Significant response should be noticed within 3 wk. Clinical studies have demonstrated continuing improvement through 9 wk of therapy. Special Populations: Reduce dose in patients with severe hepatic impairment. Reconstitution: Reconstitute powder for inj by adding 4.4 ml of sterile or bacteriostatic water for inj, 0.9% sodium chloride inj or bacteriostatic sodium chloride inj to a vial labeled as containing 500 mg metronidazole. Reconstituted solution contains approx 100 mg/ml Stomorgyl and must be further diluted with 0.9% sodium chloride inj, 5% dextrose inj or lactated Ringer\'s inj to a concentration of ≤8 mg/ml metronidazole. Neutralise reconstituted and diluted Stomorgyl hydrochloride solution by adding approx 5 mEq of sodium bicarbonate inj for each 500 mg metronidazole. Incompatibility: Incompatible with aztreonam, dopamine, meropenem.

Symptomatic TrichomoniasisMetronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of thetrichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).Asymptomatic TrichomoniasisMetronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervi-citis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts. T. vagi-nalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with Stomorgyl in cases of reinfection. AmebiasisMetronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysen-tery)and amebic liver abscess. In amebic liver abscess, Stomorgyl therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial InfectionsMetronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Stomorgyl therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Flagyl. In the treatment of most serious anaerobic infections, Stomorgyl I.V. (metronidazole hydrochloride) or Stomorgyl I.V. RTU® (metronidazole) is usually administered initially. This may be followed by oral ther-apy with Stomorgyl (metronidazole) at the discretion of the physician. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis,B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostrid-ium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger,Peptostreptococcus species, and Fusobacte-rium species. GYNECOLOGIC INFECTIONS, including endo-metritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcusniger, and Pepto-streptococcus species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group, and Clos-tridium species. BONE AND JOINT INFECTIONS, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B.fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B.fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Stomorgyl and other antibacterial drugs, Stomorgyl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Treatment of serious infections caused by susceptible anaerobic bacteria; prophylaxis of postoperative infection in patients undergoing colorectal surgery; treatment of amebiasis; treatment of trichomoniasis and asymptomatic partners of infected patients. Unlabeled use(s): Prophylaxis of postoperative infection in gynecologic and abdominal surgery; treatment of hepatic encephalopathy, Crohnâ€s disease, antibiotic-associated pseudomembranous colitis, Helicobacter pylori infections, giardiasis and Gardnerella vaginalis infections.

Stomorgyl Mylan Pharmaceuticals is an anti protozoal agent. It is believed that the mechanism of action is associated with DNA damage-sensitive microorganisms. Active

Active ingredients: Metronidazole
Unit description, dosagePrice, USD
Tablet; Oral; Metronidazole 25 mg; Spiramycin 150,000 IU / dose
Tablet; Oral; Metronidazole 125 mg; Spiramycin 750,000 IU / dose
Tablet; Oral; Metronidazole 250 mg; Spiramycin 1,500,000 IU / dose

List of stomorgyl brand and generic drugs

Stomffler
Strazyl (Bangladesh)
Sucral M
Sucral M Skin 20 gm Cream$ 0.83
Supplin (Bahrain, Cyprus, Hungary, Indonesia, Jordan, Kuwait, Lebanon, Lithuania, Qatar, Saudi Arabia, Sudan, United Arab Emirates, Yemen)
Tablet; Oral; Metronidazole 250 mg
Supplin (bottle) 500 mg/100 mL x 1's$ 6.12
Injectable; Infusion; Metronidazole 5 mg / ml
Tablets; Oral; Metronidazole 250 mg
Sutrol (Taiwan)
Sutrol 7.5 mg/1 g x 10 g
Sutrol 7.5 mg/1 g x 25 g
Syneodalin (Singapore)
Syneodalin 200 mg x 1's
T Nor
T Nor 30 ml Suspension$ 0.08
Tadagyl (Vietnam)
Tadagyl 250 mg x 10 Blister x 10 Tablet
Takimetol
Tamizol (Tunisia)
Taremis (Argentina)
Teemet
Teemet 400+333 Tablet$ 0.07
Temonas (Thailand)
Temonas 250 mg x 1000's
Tenaflox (Colombia)
Terico-S (Taiwan)
Terico-S 250 mg
Tetzole
Tetzole 400+333 Capsule$ 0.06
Tian Li Ning (China)
Tibamer
Tablet; Oral; Metronidazole 200 mg
Tablets; Oral; Metronidazole 200 mg
Tiflox M
Tiflox M 30 ml Suspension$ 0.07
Tinamax MPS
Tinamax MPS 400+500+25 Tablet$ 0.03
Tismazol (Indonesia)
Tismazol 250 mg x 10 x 10's$ 9.18
Tismazol 500 mg x 10 x 10's$ 15.30
Tolbin (Argentina)
Tolbin 1.5 mg/5 mL x 60 mL
1 g x 10's$ 0.89
600 mg x 10's$ 0.60
800 mg x 10's$ 0.74
Tolbin 2.5 mg x 1000's
Tolbin 2.5 mg x 100 x 10's
Tolbin 60 mL
Tolbin 1g TAB / 10$ 0.89
Tolbin 600mg TAB / 10$ 0.60
Tolbin 800mg TAB / 10$ 0.74
Tolbin 1000 mg Tablet$ 0.09
Tolbin 800 mg Tablet$ 0.07
Tolbin 600 mg Tablet$ 0.06
Tolizole (Taiwan)
Tolizole 250 mg
Tolizole 250 mg x Blister pk

Show all Stomorgyl generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer